MOLNNASDAQHealthcare · Biotechnology

Molecular Partners AG

$3.80+1.61%(+$0.06)

TickerSpark Score

48/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MOLN research report →

52-Week Range20% of range

Low $3.41

Current $3.80

High $5.36

Companywww.molecularpartners.com

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers.

CEO: Patrick Amstutz
IPO: 2021
Employees: 158
HQ: Schlieren, CH

Price Chart

-3.55% · this period

Valuation

Market Cap: $142.55M
P/E: -1.89
P/S: 0.00
P/B: 1.60
EV/EBITDA: -0.61
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -66.19%
ROIC: -69.14%

Growth & Income

Revenue: $0 · -100.00%
Net Income: $-61,651,000 · -14.08%
EPS: $-1.65 · -3.77%
Op Income: $-58,124,000
FCF YoY: 13.34%

Performance & Tape

52W High: $5.36
52W Low: $3.41
50D MA: $4.24
200D MA: $4.13
Beta: 1.02
Avg Volume: 3.55K

Get TickerSpark's AI analysis on MOLN

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime